Documents Page

Cell Cycle Analysis

Posted on

The cell cycle profile of a sample can be determined by staining the DNA with a fluorescent dye and measuring its intensity. The dye stains DNA stoichiometrically, allowing differentiations of cells in G0/G1, S phase, and G2/M, as well as identification of aneuploid populations. A variety of staining protocols can be adapted for different sample types, but the general analysis remains the same.
Updated 7/29/24

File: Cell-cycle-analysis.pdf

Compensation Beads

Posted on

Compensation beads offer a variety of benefits. The most obvious of these is that they allow you to save more of your cells for your experimental conditions rather than controls. Additionally, compensation beads stain more brightly and uniformly than cells, allowing for easy compensation of colors that may be only on rare events in the cells sample. Importantly, compensation beads can be used with the same antibodies you use for your experiment ensuring a perfect fluorochrome match.
Updated 9/18/17

File: Flow_TechNotes_Compensation-Beads-Tech-Note_20170918.pdf

cRGD-functionalized, DOX-conjugated, and 64Cu-labeled superparamagnetic iron oxide nanoparticles for targeted anticancer drug delivery and PET/MR imaging

Posted on

Yang et al.
Multifunctional and water-soluble superparamagnetic iron oxide (SPIO) nanocarriers were developed for targeted drug delivery and positron emission tomography/magnetic resonance imaging (PET/MRI) dualmodality
imaging of tumors with integrin avb3 expression. An anticancer drug was conjugated onto the PEGylated SPIO nanocarriers via pH-sensitive bonds. Tumor-targeting ligands, cyclo(Arg-Gly-Asp-D-Phe-Cys) (c(RGDfC)) peptides, and PET 64Cu chelators, macrocyclic 1,4,7-triazacyclononane-N, N0, N00-triacetic acid (NOTA), were conjugated onto the distal ends of the PEG arms. The effectiveness of the SPIO nanocarriers as an MRI contrast agent was evaluated via an in vitro r2 MRI relaxivity measurement. cRGD-conjugated SPIO nanocarriers exhibited a higher level of cellular uptake than cRGD-free ones in vitro. Moreover, cRGD-conjugated SPIO nanocarriers showed a much higher level of tumor accumulation than cRGD-free ones according to non-invasive and quantitative PET imaging, and ex vivo biodistribution studies. Thus, these SPIO nanocarriers demonstrated promising properties for combined targeted anticancer drug delivery and PET/MRI dual-modality imaging of tumors.

File: Yang_et_al.pdf